These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 37897088)

  • 61. [Clinical, morphological and microcirculatory criteria of local recurrence of the prostate cancer after HIFU therapy].
    Neymark AI; Tachalov MA; Neymark BA; Levin VP
    Urologiia; 2020 Jun; (3):69-76. PubMed ID: 32597589
    [TBL] [Abstract][Full Text] [Related]  

  • 62. More advantages in detecting bone and soft tissue metastases from prostate cancer using
    Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
    Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Prospective Evaluation of Focal High Intensity Focused Ultrasound for Localized Prostate Cancer.
    Nahar B; Bhat A; Reis IM; Soodana-Prakash N; Becerra MF; Lopategui D; Venkatramani V; Patel R; Madhusoodanan V; Kryvenko ON; Ritch CR; Gonzalgo ML; Punnen S; Parekh DJ
    J Urol; 2020 Sep; 204(3):483-489. PubMed ID: 32167866
    [TBL] [Abstract][Full Text] [Related]  

  • 64. HIFU as salvage first-line treatment for palpable, TRUS-evidenced, biopsy-proven locally recurrent prostate cancer after radical prostatectomy: a pilot study.
    Asimakopoulos AD; Miano R; Virgili G; Vespasiani G; Finazzi Agrò E
    Urol Oncol; 2012 Sep; 30(5):577-83. PubMed ID: 21292508
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Patient-reported functional outcomes and oncological control after primary focal cryotherapy for clinically significant prostate cancer: A Phase II mandatory biopsy-monitored study.
    Tan YG; Law YM; Ngo NT; Khor LY; Tan PH; Ong EHW; Yuen JSP; Ho HSS; Tuan JKL; Kanesvaran R; Gupta RT; Rozen S; Chua MLK; Polascik TJ; Tay KJ
    Prostate; 2023 Jun; 83(8):781-791. PubMed ID: 36895163
    [TBL] [Abstract][Full Text] [Related]  

  • 66. A prospective clinical trial of HIFU hemiablation for clinically localized prostate cancer.
    van Velthoven R; Aoun F; Marcelis Q; Albisinni S; Zanaty M; Lemort M; Peltier A; Limani K
    Prostate Cancer Prostatic Dis; 2016 Mar; 19(1):79-83. PubMed ID: 26597660
    [TBL] [Abstract][Full Text] [Related]  

  • 67. High intensity focused ultrasound with Focal-One
    Perez-Reggeti JI; Sanchez-Salas R; Sivaraman A; Linares Espinos E; de Gracia-Nieto AE; Barret E; Galiano M; Rozet F; Fregeville A; Renard-Penna R; Cathala N; Mombet A; Prapotnich D; Cathelineau X
    Actas Urol Esp; 2016 Dec; 40(10):608-614. PubMed ID: 27543259
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Prostate Specific Antigen Criteria to Diagnose Failure of Cancer Control following Focal Therapy of Nonmetastatic Prostate Cancer Using High Intensity Focused Ultrasound.
    Huber PM; Afzal N; Arya M; Boxler S; Dudderidge T; Emberton M; Guillaumier S; Hindley RG; Hosking-Jervis F; Leemann L; Lewi H; McCartan N; Moore CM; Nigam R; Odgen C; Persad R; Thalmann GN; Virdi J; Winkler M; Ahmed HU
    J Urol; 2020 Apr; 203(4):734-742. PubMed ID: 31928408
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Extensive Histological Sampling following Focal Therapy of Clinically Significant Prostate Cancer with High Intensity Focused Ultrasound.
    Mortezavi A; Krauter J; Gu A; Sonderer J; Bruhin J; Reeve KA; Held L; Donati OF; Rupp NJ; Moch H; Sulser T; Eberli D
    J Urol; 2019 Oct; 202(4):717-724. PubMed ID: 31042109
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Medium-term Outcomes after Whole-gland High-intensity Focused Ultrasound for the Treatment of Nonmetastatic Prostate Cancer from a Multicentre Registry Cohort.
    Dickinson L; Arya M; Afzal N; Cathcart P; Charman SC; Cornaby A; Hindley RG; Lewi H; McCartan N; Moore CM; Nathan S; Ogden C; Persad R; van der Meulen J; Weir S; Emberton M; Ahmed HU
    Eur Urol; 2016 Oct; 70(4):668-674. PubMed ID: 26951947
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Prostate cancer detection rate in men undergoing transperineal template-guided saturation and targeted prostate biopsy.
    Kaufmann B; Saba K; Schmidli TS; Stutz S; Bissig L; Britschgi AJ; Schaeren E; Gu A; Langenegger N; Sulser T; Eberli D; Keller EX; Hermanns T; Poyet C
    Prostate; 2022 Feb; 82(3):388-396. PubMed ID: 34914121
    [TBL] [Abstract][Full Text] [Related]  

  • 72. High-intensity focused ultrasound for the treatment of prostate cancer: A prospective trial with long-term follow-up.
    Mearini L; D'Urso L; Collura D; Nunzi E; Muto G; Porena M
    Scand J Urol; 2015; 49(4):267-74. PubMed ID: 25485722
    [TBL] [Abstract][Full Text] [Related]  

  • 73. How to make clinical decisions to avoid unnecessary prostate screening in biopsy-naïve men with PI-RADs v2 score ≤ 3?
    Zhang Y; Zeng N; Zhang F; Huang Y; Tian Y
    Int J Clin Oncol; 2020 Jan; 25(1):175-186. PubMed ID: 31473884
    [TBL] [Abstract][Full Text] [Related]  

  • 74. A multi-centre prospective development study evaluating focal therapy using high intensity focused ultrasound for localised prostate cancer: The INDEX study.
    Dickinson L; Ahmed HU; Kirkham AP; Allen C; Freeman A; Barber J; Hindley RG; Leslie T; Ogden C; Persad R; Winkler MH; Emberton M;
    Contemp Clin Trials; 2013 Sep; 36(1):68-80. PubMed ID: 23774040
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Primary Whole-gland Ablation for the Treatment of Clinically Localized Prostate Cancer: A Focal Therapy Society Best Practice Statement.
    Deivasigamani S; Kotamarti S; Rastinehad AR; Salas RS; de la Rosette JJMCH; Lepor H; Pinto P; Ahmed HU; Gill I; Klotz L; Taneja SS; Emberton M; Lawrentschuk N; Wysock J; Feller JF; Crouzet S; Kumar M P; Seguier D; Adams ES; Michael Z; Abreu A; Jack Tay K; Ward JF; Shinohara K; Katz AE; Villers A; Chin JL; Stricker PD; Baco E; Macek P; Ahmad AE; Chiu PKF; Crawford ED; Rogers CG; Futterer JJ; Rais-Bahrami S; Robertson CN; Hadaschik B; Marra G; Valerio M; Chong KT; Kasivisvanathan V; Tan WP; Lomas D; Walz J; Guimaraes GC; Mertziotis NI; Becher E; Finelli A; Kasraeian A; Lebastchi AH; Vora A; Rosen MA; Bakir B; Arcot R; Yee S; Netsch C; Meng X; de Reijke TM; Tan YG; Regusci S; Benjamin TGR; Olivares R; Noureldin M; Bianco FJ; Sivaraman A; Kim FJ; Given RW; Dason S; Sheetz TJ; Shoji S; Schulman A; Royce P; Shah TT; Scionti S; Salomon G; Laguna P; Tourinho-Barbosa R; Aminsharifi A; Cathelineau X; Gontero P; Stabile A; Grummet J; Ledbetter L; Graton M; Stephen Jones J; Polascik TJ;
    Eur Urol; 2023 Dec; 84(6):547-560. PubMed ID: 37419773
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Comparisons of Oncological and Functional Outcomes Between Primary Whole-Gland Cryoablation and High-Intensity Focused Ultrasound for Localized Prostate Cancer.
    Liu YY; Chiang PH
    Ann Surg Oncol; 2016 Jan; 23(1):328-34. PubMed ID: 26088651
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Comparison of Magnetic Resonance Imaging-stratified Clinical Pathways and Systematic Transrectal Ultrasound-guided Biopsy Pathway for the Detection of Clinically Significant Prostate Cancer: A Systematic Review and Meta-analysis of Randomized Controlled Trials.
    Woo S; Suh CH; Eastham JA; Zelefsky MJ; Morris MJ; Abida W; Scher HI; Sidlow R; Becker AS; Wibmer AG; Hricak H; Vargas HA
    Eur Urol Oncol; 2019 Nov; 2(6):605-616. PubMed ID: 31204311
    [TBL] [Abstract][Full Text] [Related]  

  • 78. The combined role of MRI prostate and prostate health index in improving detection of significant prostate cancer in a screening population of Chinese men.
    Chiu PK; Lam TY; Ng CF; Teoh JY; Cho CC; Hung HY; Hong C; Roobol MJ; Chu WC; Wong SY; Sung JJ
    Asian J Androl; 2023 Nov; 25(6):674-679. PubMed ID: 37534902
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Focal High-intensity Focussed Ultrasound Partial Gland Ablation for the Treatment of Localised Prostate Cancer: A Report of Medium-term Outcomes From a Single-center in the United Kingdom.
    Johnston MJ; Emara A; Noureldin M; Bott S; Hindley RG
    Urology; 2019 Nov; 133():175-181. PubMed ID: 31449831
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Oncological and functional outcome after partial prostate HIFU ablation with Focal-One
    Dellabella M; Branchi A; Di Rosa M; Pucci M; Gasparri L; Claudini R; Carnevali F; Cecchini S; Castellani D
    Prostate Cancer Prostatic Dis; 2021 Dec; 24(4):1189-1197. PubMed ID: 34007021
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.